SCHEMBL4894119

SCHEMBL4894119

Cc1ncc(C(=O)O)cc1Nc1nccc(-c2cccnc2)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 14/20 0.65
BCR P11274 12/20 0.65
PRKCA P17252 7/20 0.65
PDGFRB P09619 8/20 0.60
PDGFRA P16234 8/20 0.60
EGFR P00533 5/20 0.60
PRKCD Q05655 2/20 0.57
SRC P12931 2/20 0.56
PRKD3 O94806 1/20 0.55
PRKCG P05129 1/20 0.55
PRKCB P05771 1/20 0.55
PRKCH P24723 1/20 0.55
PRKCI P41743 1/20 0.55
PRKCE Q02156 1/20 0.55
PRKCQ Q04759 1/20 0.55
PRKCZ Q05513 1/20 0.55
PRKD1 Q15139 1/20 0.55
JAK3 P52333 1/20 0.55
BTK Q06187 1/20 0.55
ITK Q08881 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29707254 0.87 ABL1 (0.71) ABL1BCRPRKCAPDGFRBPDGFRA
SCHEMBL533540 0.87 ABL1 (0.71) ABL1BCRPRKCAPDGFRBPDGFRA
SCHEMBL3004681 0.83 ABL1 (0.75) ABL1BCRPRKCAPDGFRBPDGFRA
SCHEMBL29928272 0.83 ABL1 (0.61) ABL1BCRPRKCAPDGFRBPDGFRA
SCHEMBL29855980 0.83 ABL1 (0.63) ABL1BCRPRKCAPDGFRBPDGFRA
SCHEMBL29912657 0.83 ABL1 (0.75) ABL1BCRPRKCAPDGFRBPDGFRA
SCHEMBL28401628 0.83 ABL1 (0.63) ABL1BCRPRKCAPDGFRBPDGFRA
SCHEMBL23798722 0.83 ABL1 (0.66) ABL1BCRPRKCAPDGFRBPDGFRA
SCHEMBL4382247 0.82 PDGFRB (0.71) ABL1BCRPRKCAPDGFRBPDGFRA
SCHEMBL4370091 0.82 ABL1 (0.80) ABL1BCRPRKCAPRKCDSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1840122-B1 AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF SUN PIAOYANG (CN) 2013-08-28 EP disclosed
US-8183242-B2 Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof Sun, Piaoyang (CN) 2012-05-22 US disclosed
US-20080312251-A1 Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2008-12-18 US disclosed
EP-1840122-A1 AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF Sun, Piaoyang (CN) 2007-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312251-A1 Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof DPYD, PKN2, TYMP ABL1 7/4885BCR 2529/4885PRKCA 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.